Cell surface delivery of TRAIL strongly augments the tumoricidal activity of T cells

Clinical Cancer Research

Volumn 17, Issue 17, 2011, Pages 5626-5637

  De Bruyn, Marco ^a   Wei, Yunwei ^a,c   Wiersma, Valerie R ^a   Samplonius, Douwe F ^a   Klip, Harry G ^b   Van Der Zee, Ate G J ^b   Yang, Baofeng ^c   Helfrich, Wijnand ^a   Bremer, Edwin ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; CD7 ANTIGEN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL SURFACE; COLORECTAL CARCINOMA; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE ACTIVATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; SOLID TUMOR; T LYMPHOCYTE; TUMOR XENOGRAFT;

ANIMALS; ANTIGENS, CD3; ANTIGENS, CD7; APOPTOSIS; CELL LINE, TUMOR; CELL MEMBRANE; CYTOTOXICITY, IMMUNOLOGIC; GRAFT VS TUMOR EFFECT; HUMANS; MICE; NEOPLASMS; RECEPTORS, TUMOR NECROSIS FACTOR; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES, CYTOTOXIC; TNF-RELATED APOPTOSIS-INDUCING LIGAND; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 80052438224     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-0303     Document Type: Article

References (26)

1. Chouaib S., Meslin F., Thiery J., Mami-Chouaib F. Tumor resistance to specific lysis: A major hurdle for successful immunotherapy of cancer. Clin Immunol 2009;130:34-40.
2. Lee H., Timme T., Thompson T. Resistance to lysis by cytotoxic T cells: A dominant effect in metastatic mouse prostate cancer cells. Cancer Res 2000;60:1927-1933 (Pubitemid 30207654)
3. Abouzahr-Rifai S., Hasmim M., Boukerche H., Hamelin J., Janji B., Jalil A., et al. Resistance of tumor cells to cytolytic T lymphocytes involves Rho-GTPases and focal adhesion kinase activation. J Biol Chem 2008;283:31665-31672
4. Otten H.G., Van Ginkel W.G., Hagenbeek A., Petersen E.J. Prevalence and clinical significance of resistance to perforin- and FAS-mediated cell death in leukemia. Leukemia 2004;18:1401-1405 (Pubitemid 39136750)
5. Hamai A., Meslin F., Benlalam H., Jalil A., Mehrpour M., Faure F., et al. ICAM-1 has a critical role in the regulation of metastatic melanoma tumor susceptibility to CTL lysis by interfering with PI3K/AKT pathway. Cancer Res 2008;68:9854-9864
6. Suda T., Hashimoto H., Tanaka M., Ochi T., Nagata S. Membrane Fas ligand kills human peripheral blood T lymphocytes, and soluble Fas ligand blocks the killing. J Exp Med 1997;186:2045-2050 (Pubitemid 28013689)
7. Hallermalm K., De Geer A., Kiessling R., Levitsky V., Levitskaya J. Autocrine secretion of Fas ligand shields tumor cells from Fas-mediated killing by cytotoxic lymphocytes. Cancer Res 2004;64: 6775-6782 (Pubitemid 39297941)
8. Takeda K., Hayakawa Y., Smyth M.J., Kayagaki N., Yamaguchi N., Kakuta S., et al. Involvement of tumor necrosis factor-relatedapoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells. Nat Med 2001;7:94-100. (Pubitemid 32095647)
9. Cretney E., Takeda K., Yagita H., Glaccum M., Peschon J.J., Smyth M.J. Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice. J Immunol 2002;168:1356-1361 (Pubitemid 34094506)
10. Schmaltz C., Alpdogan O., Kappel B.J., Muriglan S.J., Rotolo J.A., Ongchin J., et al. T cells require TRAIL for optimal graft-versus-tumor activity. Nat Med 2002;8:1433-1437 (Pubitemid 36019429)
11. Kayagaki N., Yamaguchi N., Nakayama M., Eto H., Okumura K., Yagita H. Type I interferons (IFNs) regulate tumor necrosis factor-related apoptosis- inducing ligand (TRAIL) expression on human T cells: A novel mechanism for the antitumor effects of type I IFNs. J Exp Med 1999; 189:1451-1460 (Pubitemid 29227531)
12. Tian J.Q., Wang Z.P., Rodriguez R., Fu J.S., Lu J.Z., Ma B.L. In vitro enhanced cytotoxicity of tumor-infiltrating lymphocytes transfected with tumor necrosis factor-related apoptosis-inducing ligand and/or interleukin-2 gene in human renal cell carcinoma. Urology 2006; 67:1093-1098 (Pubitemid 43964821)
13. Bremer E., De Bruyn M., Wajant H., Helfrich W. Targeted cancer immunotherapy using ligands of the tumor necrosis factor superfamily. Curr Drug Targets 2009;10:94-103.
14. Bremer E., Kuijlen J., Samplonius D., Walczak H., De Leij L., Helfrich W. Target cell-restricted and -enhanced apoptosis induction by a scFv: STRAIL fusion protein with specificity for the pancarcinoma-associated antigen EGP21. Int J Cancer 2004;109:281-290 (Pubitemid 38240933)
15. Li Y.C., Chen B.M., Wu P.C., Cheng T.L., Kao L.S., Tao M.H., et al. Cutting Edge: Mechanical forces acting on T cells immobilized via the TCR complex can trigger TCR signaling. J Immunol 2010;184:5959-5963
16. Leng C., Gries M., Ziegler J., Lokshin A., Mascagni P., Lentzsch S., et al. Reduction of graft-versus-host disease by histone deacetylase inhibitor suberonylanilide hydroxamic acid is associated with modulation of inflammatory cytokine milieu and involves inhibition of STAT1. Exp Hematol 2006;34:776-787 (Pubitemid 43737091)
17. Reddy P., Sun Y., Toubai T., Duran-Struuck R., Clouthier S.G., Weisiger E., et al. Histone deacetylase inhibition modulates indoleamine 2,3-dioxygenase- dependent DC functions and regulates experimental graftversus- host disease in mice. J Clin Invest 2008;118:2562-2573 (Pubitemid 351949783)
18. Fulda S. Modulation of TRAIL-induced apoptosis by HDAC inhibitors. Curr Cancer Drug Targets 2008;8:132-140 (Pubitemid 351347249)
19. Panner A., Parsa A.T., Pieper R.O. Use of APO2L/TRAIL with mTOR inhibitors in the treatment of glioblastoma multiforme. Expert Rev Anticancer Ther 2006;6:1313-1322 (Pubitemid 44575582)
20. Hartwig U.F., Nonn M., Khan S., Meyer R.G., Huber C., Herr W. Depletion of alloreactive T cells via CD69: Implications on antiviral, antileukemic and immunoregulatory T lymphocytes. Bone Marrow Transplant 2005;37:297-305.
21. Barber L.D., Madrigal J.A. Exploiting beneficial alloreactive T cells. Vox Sang 2006;91:20-27 (Pubitemid 43822300)
22. Kim S.T., Takeuchi K., Sun Z.Y., Touma M., Castro C.E., Fahmy A., et al. The alphabeta T cell receptor is an anisotropic mechanosensor. J Biol Chem 2009;284:31028-31037
23. Ghez D., Rubio M.T., Maillard N., Suarez F., Chandesris M.O., Delarue R., et al. Rapamycin for refractory acute graft-versus-host disease. Transplantation 2009;88:1081-1087
24. Riley J.L., June C.H. The CD28 family: A T-cell rheostat for therapeutic control of T-cell activation. Blood 2005;105:13-21. (Pubitemid 40053057)
25. Egen J., Kuhns M., Allison J. CTLA-4: New insights into its biological function and use in tumor immunotherapy. Nat Immunol 2002;3: 611-618 (Pubitemid 34752469)
26. Razmara M., Hilliard B., Ziarani A.K., Murali R., Yellayi S., Ghazanfar M., et al. Fn14-TRAIL, a chimeric intercellular signal exchanger, attenuates experimental autoimmune encephalomyelitis. Am J Pathol 2009; 174:460-474